Head-to-head · WeighScore
Henry Meds vs Ro
The verdict
Ro takes it — 78/100 to 76/100, but only just.
Ro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A heavyweight platform with brand-name access — but opaque compounded pricing drags its score. Henry Meds is close behind and may still be the better fit — see the factor split below.
Both are editorial reviews with no commercial relationship.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Henry Meds | Ro |
|---|---|---|
| WeighScore | 76/100 | 78/100 |
| Grade | C | C+ |
| Scorecard rank | #25 | #24 |
| Semaglutide | $249/mo | Not disclosed |
| Tirzepatide | $349/mo | Not disclosed |
| Coverage | Multi-state | Multi-state |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
| Relationship | Editorial | Editorial |
Graded #25 · C
Strengths
- Simple flat-fee model
- Established brand
- Both molecules
Where it loses points
- Higher pricing than newer entrants
- Compounded only
Graded #24 · C+
Strengths
- Brand-name access + insurance support
- Oral options
- Well-funded platform
Where it loses points
- Does not disclose compounded pricing up front
- Premium positioning
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.